This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bard Announces First Quarter Results

Stocks in this article: BCR

C. R. Bard, Inc. (NYSE: BCR) today reported 2012 first quarter financial results. First quarter 2012 net sales were $730.0 million, an increase of 4 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2012 net sales increased 5 percent over the prior-year period.

For the first quarter 2012, net sales in the U.S. were $496.2 million, an increase of 2 percent over the prior-year period. Net sales outside the U.S. were $233.8 million, an increase of 10 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, first quarter 2012 net sales outside the U.S. increased 11 percent over the prior-year period.

For the first quarter 2012, net income was $138.7 million and diluted earnings per share available to common shareholders were $1.60, an increase of 5 percent and 7 percent, respectively, as compared to first quarter 2011 results. Adjusting for items that affect comparability between periods as detailed in the tables below, first quarter 2012 net income was $139.5 million and diluted earnings per share available to common shareholders were $1.61, an increase of 4 percent and 7 percent, respectively, as compared to first quarter 2011 results.

Timothy M. Ring, chairman and chief executive officer, commented, “The results this quarter reflect a good start to the year. While we haven’t seen much change in the U.S. environment, our increased focus and investments in international markets have provided rapid returns and strengthened our growth profile. We remain focused on daily execution of our product leadership strategy to take advantage of current opportunities while positioning ourselves for stronger growth in the future.”

C. R. Bard, Inc. ( www.crbard.com ), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our December 31, 2011 Form 10-K for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Consolidated Statements of Income
(dollars and shares in thousands except per share amounts, unaudited)
         
Quarter Ended
March 31,

2012

2011

 
Net sales $ 730,000 $ 700,300
Costs and expenses
Cost of goods sold 279,400 264,800
Marketing, selling and administrative expense 202,300 194,300
Research and development expense 48,200 48,000
Interest expense 9,500 9,100
Other (income) expense, net   (800 )   100
 
Total costs and expenses   538,600     516,300
Income from operations before income taxes   191,400     184,000
 
Income tax provision   52,700     52,100
Net income $ 138,700   $ 131,900
 
Basic earnings per share available to common shareholders $ 1.62   $ 1.52
 
Diluted earnings per share available to common shareholders $ 1.60   $ 1.49
 
Wt. avg. common shares outstanding - basic 84,100 85,300
 
Wt. avg. common and common equivalent shares outstanding - diluted 85,100 87,000
 
 
Product Group Summary of Net Sales
(dollars in thousands, unaudited)
           
 
Quarter Ended March 31,
Constant
2012   2011     Change   Currency
Vascular $ 209,200 $ 198,300 5 % 6 %
Urology 185,100 179,500 3 % 3 %
Oncology 198,900 186,400 7 % 7 %
Surgical Specialties 114,700 114,900 - -
Other   22,100   21,200   4 % 5 %
 
Net sales $ 730,000 $ 700,300   4 %
 
Foreign exchange impact     (2,300 )
Constant Currency $ 730,000 $ 698,000   5 %
 
 
Reconciliation of Earnings
(dollars in millions except per share amounts, unaudited)
                           
 
Quarter Ended March 31, 2012
Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net   Taxes Income Shareholders
 
GAAP Basis $ 279.4 $ 202.3 $ 48.2 $ (0.8 ) $ 52.7 $ 138.7 $ 1.60

Items that affect comparability of results between periods:

 
Acquisition related items - - (0.4 ) (0.6 ) 0.2 0.8 0.01
             
Adjusted Basis $ 279.4 $ 202.3   $ 47.8   $ (1.4 ) $ 52.9 $ 139.5 $ 1.61
 
 
Quarter Ended March 31, 2011
Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net   Taxes Income Shareholders
 
GAAP Basis $ 264.8 $ 194.3 $ 48.0 $ 0.1 $ 52.1 $ 131.9 $ 1.49

Items that affect comparability of results between periods:

 
Acquisition related items 0.6 (0.2 ) (3.0 ) (0.2 ) 1.0 1.8 0.02
             
Adjusted Basis $ 265.4 $ 194.1   $ 45.0   $ (0.1 ) $ 53.1 $ 133.7 $ 1.51
 
 

Notes to Reconciliation of Earnings

  • For the three months ended March 31, 2012, a charge of $1.0 million pre-tax for acquisition-related items including transaction costs, purchase accounting adjustments and integration costs, affected the comparability of results between periods. The effect of this charge decreased net income by $0.8 million, or $0.01 diluted earnings per share available to common shareholders.
  • For the three months ended March 31, 2011, a charge of $2.8 million pre-tax for acquisition-related items including purchased research and development, transaction costs, purchase accounting adjustments and integration costs, affected the comparability of results between periods. The effect of this charge decreased net income by $1.8 million, or $0.02 diluted earnings per share available to common shareholders.

This press release contains financial measures that are not calculated in accordance with United States generally accepted accounting principles (GAAP). These non-GAAP measures are reconciled to their most directly comparable GAAP measures in the above tables.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs